Skip to main content

Table 1 Characteristics of each study

From: Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis

First author

Year

Country

Cancer types

Sample size

Cut off

Median age

Median follow-up (month)

Research type

Survival analysis

HR type

NOS

Mahmoud

2012

UK

Primary invasive BC

1214

1 cell

55

250

Retrospective analysis

BCSS

Reported

6

Garaud 1

2019

Belgium

HER2 + BC

136

0.055

NR

120

Retrospective analysis

OS, DFS

Reported

8

Garaud 2

2019

Belgium

TNBC

113

0.0275

NR

120

Retrospective analysis

OS, DFS

Reported

8

Arias-Pulido

2018

Algeria

IBC

221

0.01

NR

96

Retrospective analysis

OS, DFS

Estimated

5

Yeong

2018

Singapore

TNBC

269

0.05

55

97

Retrospective analysis

OS, DFS

Reported

7

Xu

2018

China

Invasive ductal BC

102

115 cells

48

60

Retrospective analysis

OS, DFS

Reported

6

Mohammed

2013

UK

Primary operable ductal invasive BC

338

5 cells

NR

164

Retrospective analysis

BCSS

Reported

8

Boissière-Michot

2020

France

TNBC

105

NR

NR

120

Retrospective analysis

RFS

Reported

7

Yu

2013

China

BC

130

NR

NR

NR

Retrospective analysis

OS, DFS

Estimated

6

  1. BC breast cancer; TNBC triple-negative breast cancer; IBC inflammatory breast cancer; HER2 human epidermal growth factor receptor-2; NR not reported; BCSS breast cancer-specific survival; OS overall survival; DFS disease-free survival; RFS relapse-free survival; HR hazard ratio; NOS Newcastle-Ottawa Quality Assessment Scale